Brokerages Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $86.80

Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) has received a consensus recommendation of "Buy" from the six ratings firms that are presently covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $86.80.

Several equities analysts have recently weighed in on the stock. Morgan Stanley assumed coverage on shares of Structure Therapeutics in a research note on Monday, September 23rd. They issued an "overweight" rating and a $118.00 price objective on the stock. JMP Securities decreased their target price on shares of Structure Therapeutics from $91.00 to $86.00 and set a "market outperform" rating on the stock in a research note on Friday, August 9th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $65.00 target price on shares of Structure Therapeutics in a research note on Monday, September 23rd.

Structure Therapeutics Stock Up 0.3 %

Shares of NASDAQ GPCR traded up $0.13 during trading on Friday, reaching $37.59. 625,342 shares of the company traded hands, compared to its average volume of 672,980. The firm has a 50 day simple moving average of $39.62 and a 200-day simple moving average of $39.78. The stock has a market capitalization of $2.15 billion, a PE ratio of -50.12 and a beta of -3.53. Structure Therapeutics has a 52-week low of $26.61 and a 52-week high of $75.02.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.05. As a group, research analysts predict that Structure Therapeutics will post -0.79 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Sandia Investment Management LP purchased a new position in shares of Structure Therapeutics in the second quarter valued at $39,000. Quarry LP purchased a new position in Structure Therapeutics during the second quarter worth $79,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Structure Therapeutics by 60.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company's stock worth $158,000 after buying an additional 1,420 shares during the period. Bank Pictet & Cie Europe AG purchased a new position in Structure Therapeutics during the third quarter worth $206,000. Finally, Sei Investments Co. purchased a new position in Structure Therapeutics during the second quarter worth $212,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.